TABLE 4
FROM:
Results of donor lymphocyte infusions for relapsed myelodysplastic syndrome after hematopoietic cell transplantation
P V Campregher, T Gooley, B L Scott, C Moravec, B Sandmaier, P J Martin, H J Deeg, E H Warren and M E D Flowers
BACK TO ARTICLETable 4. Summary of previous reports and current series of treatment with DLI for recurrent MDS
| Study | No. of patients | Donor type | Median age | Median months from transplant to relapse | DLI cell dose kg -1 (median) | Complete response (%) |
|---|---|---|---|---|---|---|
| Current series | 16 | 12 MRD/4 MUD | 48 | 7 | 1  108 CD3+ | 3/14 (20) |
| Depil et al. 7 | 14 | 13 MRD/1 MUD | 46 | 10 | 6.3 107 CD3+ | 2/14 (14) |
| Shiobara et al. 14 | 11 | 10 MRD/1 MMUD | 24 | 8 | 3.9 108 TNC | 3/11 (27) |
| Ho et al. 19 | 10 | 6 MRD/4 MUD | 53 | NA | 0.8 107 CD3+ | 4/10 (40) |
| Collins et al. 10 | 6 | 6 MRD | 40 | NA | 7.3 108 MNC | 2/5 (40) |
| Kolb et al. 11 | 5 | 5 MRD | 39 | 12 | 7.6 108 MNC | 1/4 (25) |
Abbreviations: MRD=matched related donors; MUD=matched unrelated donors; NA=not available.
